Jeil Pharma Holdings Inc (KRX: 002620)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,230.00
-120.00 (-1.44%)
Nov 15, 2024, 3:30 PM KST

Jeil Pharma Holdings Statistics

Total Valuation

Jeil Pharma Holdings has a market cap or net worth of KRW 126.34 billion. The enterprise value is 337.02 billion.

Market Cap 126.34B
Enterprise Value 337.02B

Important Dates

The last earnings date was Monday, November 11, 2024.

Earnings Date Nov 11, 2024
Ex-Dividend Date n/a

Share Statistics

Jeil Pharma Holdings has 15.35 million shares outstanding.

Current Share Class n/a
Shares Outstanding 15.35M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 76.13%
Owned by Institutions (%) 0.02%
Float 2.17M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.16
PB Ratio 0.38
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 117.55, with an EV/FCF ratio of -56.43.

EV / Earnings -8.52
EV / Sales 0.43
EV / EBITDA 117.55
EV / EBIT n/a
EV / FCF -56.43

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.35.

Current Ratio 1.03
Quick Ratio 0.66
Debt / Equity 0.35
Debt / EBITDA 52.71
Debt / FCF -25.30
Interest Coverage -1.01

Financial Efficiency

Return on equity (ROE) is -13.51% and return on invested capital (ROIC) is -1.09%.

Return on Equity (ROE) -13.51%
Return on Assets (ROA) -0.73%
Return on Capital (ROIC) -1.09%
Revenue Per Employee 20.09B
Profits Per Employee -1.01B
Employee Count 39
Asset Turnover 0.88
Inventory Turnover 4.34

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -17.62% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -17.62%
50-Day Moving Average 8,718.20
200-Day Moving Average 9,841.00
Relative Strength Index (RSI) 34.90
Average Volume (20 Days) 6,092

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Jeil Pharma Holdings had revenue of KRW 783.56 billion and -39.54 billion in losses. Loss per share was -2,575.85.

Revenue 783.56B
Gross Profit 206.27B
Operating Income -10.47B
Pretax Income -55.62B
Net Income -39.54B
EBITDA 2.87B
EBIT -10.47B
Loss Per Share -2,575.85
Full Income Statement

Balance Sheet

The company has 48.04 billion in cash and 151.11 billion in debt, giving a net cash position of -103.07 billion or -6,714.04 per share.

Cash & Cash Equivalents 48.04B
Total Debt 151.11B
Net Cash -103.07B
Net Cash Per Share -6,714.04
Equity (Book Value) 436.29B
Book Value Per Share 21,410.33
Working Capital 10.95B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.49 billion and capital expenditures -4.48 billion, giving a free cash flow of -5.97 billion.

Operating Cash Flow -1.49B
Capital Expenditures -4.48B
Free Cash Flow -5.97B
FCF Per Share -389.06
Full Cash Flow Statement

Margins

Gross margin is 26.33%, with operating and profit margins of -1.34% and -5.05%.

Gross Margin 26.33%
Operating Margin -1.34%
Pretax Margin -7.10%
Profit Margin -5.05%
EBITDA Margin 0.37%
EBIT Margin -1.34%
FCF Margin -0.76%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.61%.

Dividend Per Share 50.00
Dividend Yield 0.61%
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield 0.61%
Earnings Yield -31.30%
FCF Yield -4.73%
Dividend Details

Stock Splits

The last stock split was on April 17, 2006. It was a forward split with a ratio of 10.

Last Split Date Apr 17, 2006
Split Type Forward
Split Ratio 10

Scores

Jeil Pharma Holdings has an Altman Z-Score of 1.2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.2
Piotroski F-Score n/a